Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc develops and manufactures therapeutic medical devices and healthcare technology for chronic diseases and procedural care. Its news commonly covers regulatory clearances and CE marks, product launches, clinical data, acquisitions, and financial results across cardiovascular, cardiac rhythm management, cranial and spinal technologies, surgical navigation, robotics, and ablation systems.
Recent company updates include the Stealth AXiS™ surgical system for planning, navigation, and robotics; the Affera™ mapping and ablation system with Sphere-9™ and Sphere-360™ catheters; the OmniaSecure™ defibrillation lead; and the completed CathWorks acquisition, including the FFRangio® System for coronary artery disease assessment.
Medtronic (MDT) received FDA clearance for the LigaSure™ RAS Maryland jaw instrument on its Hugo™ robotic-assisted surgery (RAS) system.
The decision adds Medtronic’s LigaSure vessel-sealing technology to the Hugo RAS instrument portfolio for U.S. robotic-assisted procedures. The LigaSure RAS Maryland device, used with the Valleylab™ FT10 energy platform, seals and cuts vessels, thick tissue, and lymphatics up to 7 mm in diameter in approximately 2 seconds while aiming to minimize thermal spread. It is the first robotic-driven LigaSure instrument and is based on technology used in more than 45 million procedures across over 65 countries. The device was previously introduced on the Hugo RAS system in Europe in 2025 following CE Mark.
Medtronic (MDT) launched an exchange offer on September 14, 2026 to divest at least 80.1% of MiniMed Group.
MiniMed, its former Diabetes business now trading as MMED, was IPO’d in March 2026, with Medtronic retaining about 90% (252,813,348 shares). The offer lets Medtronic shareholders swap Medtronic ordinary shares for MiniMed common stock, generally on a tax-free basis for U.S. federal income tax purposes, at a 7% discount, subject to an upper limit of 4.5939 MiniMed shares per Medtronic share.
If the cap does not apply, tendering holders are expected to receive MiniMed shares worth about $107.53 for each $100 of Medtronic stock tendered. Medtronic is offering up to 225,361,295 MiniMed shares, and may exchange an additional 27,452,053 shares if the offer is oversubscribed, fully exiting MiniMed. Completion requires at least 112,680,647 MiniMed shares to be issued in the offer and a favorable tax opinion.
MiniMed (MMED) filed a Form S-4 registration statement with the SEC on September 14, 2026, supporting Medtronic’s (MDT) exchange offer for MiniMed shares.
The offer covers up to 225,361,295 MiniMed shares, representing 80.1% of MiniMed’s outstanding common stock, to be exchanged for Medtronic ordinary shares that are validly tendered and not validly withdrawn. If oversubscribed, Medtronic intends to exchange its remaining 27,452,053 MiniMed shares without extending the offer period. Medtronic currently owns approximately 89.86% of MiniMed, and if the exchange offer and related transactions are completed, Medtronic will no longer hold an equity stake in MiniMed.
Teleflex (TFX) appointed veteran medical technology executive Sean M. Salmon to its Board of Directors, effective September 8, 2026.
Salmon brings over 30 years of global leadership experience in medical devices and pharmaceuticals, including more than 20 years at Medtronic (MDT), where he most recently served as Executive Vice President and President of the Cardiovascular Portfolio, a business with fiscal 2025 revenue of approximately $12.5 billion. He has also led Medtronic’s Diabetes, Coronary and Structural Heart, and Coronary and Renal Denervation businesses and currently serves as an independent director of Adagio Medical Holdings (ADGM).
With his appointment, the Teleflex Board now has nine directors, eight of whom are independent, and one third of the Board has been refreshed in 2026. Salmon will also join the Board’s Growth and Operating Committee, which was created to support Teleflex’s strategic transformation and operational execution.
Medtronic (MDT) will participate in two investor conferences in September 2026, featuring its top executives in Q&A sessions about the company.
The company will appear at the 2026 Wells Fargo Healthcare Conference/b) on , with chairman and CEO Geoff Martha and executive vice president and CFO Thierry Piéton taking questions. It will also participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:05 p.m. ET (3:05 p.m. CT), where Thierry Piéton will answer questions.
Live webcasts and same-day archived sessions for both events will be accessible via the Investors Events section at http://investorrelations.medtronic.com.
Medtronic (NYSE: MDT) reported first quarter FY27 revenue of $9.756 billion, up 13.7% reported and organic, including an estimated $570 million benefit from an extra fiscal week. GAAP diluted EPS was $1.14 and non-GAAP diluted EPS $1.45, both rising over 40% and 15%, respectively.
Cardiovascular revenue grew 19.5%, Neuroscience 10.3%, Medical Surgical 10.0%, and Diabetes 16.9%. Medtronic raised FY27 organic revenue growth guidance to 7.25%-7.75% and non-GAAP EPS guidance to $5.94–$6.00. The quarter included CE Mark expansion for Affera technologies, FDA clearance for Touch Surgery Aide, a strategic partnership with Cornerstone Robotics, an investment in Pi-Cardia, and completed acquisitions of Scientia Vascular and SPR Therapeutics.
Medtronic (NYSE: MDT) announced a strategic partnership with Cornerstone Robotics that includes an approximately $700 million investment and rights for Medtronic to distribute Cornerstone’s Sentire™ surgical system in select markets outside the U.S. where it is approved.
Medtronic will offer Sentire alongside its Hugo™ robotic-assisted surgery (RAS) system, aiming to expand global access to minimally invasive, robotic-assisted surgery and give surgeons and health systems more choice and flexibility. Hugo is now used in more than 35 countries across six continents, with procedure growth exceeding two times the robotic surgery market and total procedures expected to surpass 50,000 globally by the end of Medtronic’s fiscal year.
Sentire, developed by Cornerstone Robotics, has completed multi-specialty clinical trials and received CE Mark in May 2026 for several minimally invasive procedures, and it is already approved in China and Singapore. Medtronic plans to continue enhancing the Hugo platform and its connected digital ecosystem, including software updates, AI capabilities, and expanded instrumentation.
Medtronic (NYSE: MDT) announced a strategic investment in Pi-Cardia, securing an option to strengthen its structural heart portfolio focused on complex transcatheter aortic valve replacement (TAVR). Medtronic will invest up to $80 million in Pi-Cardia and is expected to become the exclusive global commercial distributor of Pi-Cardia’s FDA-cleared ShortCut leaflet modification device in 2027.
The agreement also grants Medtronic an option to acquire Pi-Cardia after predefined milestones for an estimated upfront price of up to $210 million, plus potential earn-out payments. ShortCut demonstrated 100% successful leaflet splitting in pivotal trial patients with a favorable safety profile. Transactions remain subject to regulatory approval and customary closing conditions.
Medtronic (NYSE: MDT) announced that its board of directors approved a $0.72 cash dividend per ordinary share for the second quarter of fiscal year 2027. The dividend will be payable on October 16, 2026, to shareholders of record as of September 25, 2026. The company noted this quarterly dividend is consistent with the dividend increase announced in June 2026 and highlighted its inclusion in the S&P 500 Dividend Aristocrats index, reflecting 49 consecutive years of annual dividend increases.
Orchestra BioMed (Nasdaq: OBIO) reported second quarter 2026 results and updates on its pivotal cardiovascular programs. The BACKBEAT global pivotal trial of AVIM Therapy, conducted with Medtronic, is on track to reach 284 evaluable randomized patients by the end of Q3 2026, with primary endpoint data presentation targeted for Q2 2027. The Virtue SAB pivotal trial for coronary in-stent restenosis continues to progress with additional site activations and patient enrollment, and AVIM Therapy received a second FDA Breakthrough Device Designation.
According to Orchestra BioMed, Q2 2026 cash, cash equivalents and marketable securities totaled $110.0 million, including $35 million in new strategic capital from Medtronic and Ligand, providing projected runway into Q4 2027. Q2 revenue was $0.1 million, research and development expenses were $16.6 million (up 20% year over year), selling, general and administrative expenses were $5.8 million (down 7%), and net loss attributable to common stockholders was $24.1 million, or ($0.38) per share. The company was added to the Russell 3000 and Russell 2000 indexes and plans an R&D Day on November 12, 2026, in New York City.